Fenwick & West represented DexCom, Inc. (Nasdaq: DXCM), a leader in continuous glucose monitoring systems for people with diabetes, in its private offering of $1.05 billion of convertible senior notes due 2025 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.

DexCom will use the net proceeds from the offering for capital expenditures, working capital and general corporate purposes, which may include in-licensing or acquisitions of, or investments in, other businesses, products or technologies, or additional note repurchases or any share repurchases. More information can be obtained from the company’s announcement​.

The Fenwick transaction team included corporate partners Michael Brown and David Michaels, as well as associates Julia Forbess, Alice Lin, Larry Suh and John Clancy.

Login

Don’t have an account yet?

Register